Q2 Earnings Forecast for Ardelyx Issued By HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Ardelyx in a report released on Wednesday, June 18th. HC Wainwright analyst M. Caufield expects that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx's Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.19) EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.63 EPS and FY2029 earnings at $1.15 EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.07). The business had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. Ardelyx had a negative net margin of 14.86% and a negative return on equity of 34.45%. The firm's revenue for the quarter was up 61.1% compared to the same quarter last year. During the same period last year, the business posted ($0.11) EPS.

ARDX has been the topic of a number of other research reports. Cantor Fitzgerald raised Ardelyx to a "strong-buy" rating in a research note on Tuesday, March 4th. Scotiabank assumed coverage on Ardelyx in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price on the stock. Raymond James Financial lowered Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 target price on the stock. in a research note on Friday, May 2nd. Piper Sandler raised Ardelyx to a "hold" rating in a research note on Wednesday, March 12th. Finally, BTIG Research assumed coverage on Ardelyx in a research note on Tuesday, March 4th. They issued a "buy" rating and a $14.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Ardelyx has an average rating of "Moderate Buy" and an average target price of $10.89.

Ardelyx Trading Up 1.4%

NASDAQ ARDX traded up $0.05 during trading hours on Monday, hitting $3.68. The company's stock had a trading volume of 2,868,660 shares, compared to its average volume of 4,514,602. The stock has a fifty day moving average of $4.04 and a 200 day moving average of $4.79. The company has a quick ratio of 3.81, a current ratio of 4.12 and a debt-to-equity ratio of 1.04. Ardelyx has a twelve month low of $3.21 and a twelve month high of $8.06. The firm has a market capitalization of $880.48 million, a P/E ratio of -16.73 and a beta of 0.59.

Insiders Place Their Bets

In other Ardelyx news, CFO Justin A. Renz sold 7,218 shares of the stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total value of $29,449.44. Following the completion of the sale, the chief financial officer now directly owns 416,089 shares in the company, valued at $1,697,643.12. This represents a 1.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David M. Mott purchased 381,377 shares of the stock in a transaction on Friday, May 2nd. The stock was acquired at an average price of $4.22 per share, with a total value of $1,609,410.94. Following the completion of the acquisition, the director now directly owns 2,396,871 shares of the company's stock, valued at approximately $10,114,795.62. This represents a 18.92% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 881,377 shares of company stock worth $3,402,411 and sold 166,809 shares worth $708,914. Corporate insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Ardelyx

Several large investors have recently modified their holdings of the business. Ensign Peak Advisors Inc grew its holdings in shares of Ardelyx by 3.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 73,950 shares of the biopharmaceutical company's stock worth $375,000 after buying an additional 2,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Ardelyx by 2.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 154,625 shares of the biopharmaceutical company's stock worth $788,000 after buying an additional 3,550 shares in the last quarter. Swiss National Bank grew its holdings in shares of Ardelyx by 1.0% during the fourth quarter. Swiss National Bank now owns 463,100 shares of the biopharmaceutical company's stock worth $2,348,000 after buying an additional 4,800 shares in the last quarter. Orion Portfolio Solutions LLC grew its holdings in shares of Ardelyx by 42.7% during the fourth quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company's stock worth $84,000 after buying an additional 4,933 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Ardelyx during the fourth quarter worth about $25,000. 58.92% of the stock is currently owned by institutional investors.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.